In support of anti-PD-1 therapy for HCC patients with oncofetal FOLR2+ TAMs expressing PD-L1, a murine model of PD-L1 knockout tumors indicated that PD-1–PD-L1 antagonism enhances the anti-tumor efficacy of myeloid cells, with this pathway inhibiting TAM function [125]. The gene discussed is CD274; the disease is neoplasm.